Clinical trials
Completed Phase 1/2 trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
244 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 8 |
| 2009 | 12 |
| 2010 | 11 |
| 2011 | 9 |
| 2012 | 10 |
| 2013 | 9 |
| 2014 | 18 |
| 2015 | 16 |
| 2016 | 19 |
| 2017 | 12 |
| 2018 | 23 |
| 2019 | 28 |
| 2020 | 22 |
| 2021 | 12 |
| 2022 | 7 |
| 2023 | 8 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 244 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asan Medical Center | 12 |
| Yonsei University | 11 |
| Hoffmann-La Roche | 9 |
| Novartis Pharmaceuticals | 9 |
| Seoul National University Hospital | 9 |
| Samsung Medical Center | 7 |
| Bristol-Myers Squibb | 6 |
| Merck Sharp & Dohme LLC | 6 |
| Green Cross Corporation | 5 |
| AstraZeneca | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stomach Neoplasms | 22 |
| Carcinoma, Non-Small-Cell Lung | 20 |
| Neoplasms | 15 |
| Breast Neoplasms | 13 |
| Carcinoma, Hepatocellular | 13 |
| Leukemia, Myeloid, Acute | 8 |
| Colorectal Neoplasms | 7 |
| Lymphoma, Non-Hodgkin | 7 |
| Carcinoma, Renal Cell | 6 |
| Cholangiocarcinoma | 6 |
Trials
Showing 1 to 25 of 244. Each trial links to its page on Pharma Observatory.
144 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.